Stereotaxis Inc (STXS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Stereotaxis Inc stock (STXS) is currently trading at $1.88. Stereotaxis Inc PS ratio (Price-to-Sales) is 5.38. Analyst consensus price target for STXS is $4.20. WallStSmart rates STXS as Sell.
- STXS PE ratio analysis and historical PE chart
- STXS PS ratio (Price-to-Sales) history and trend
- STXS intrinsic value — DCF, Graham Number, EPV models
- STXS stock price prediction 2025 2026 2027 2028 2029 2030
- STXS fair value vs current price
- STXS insider transactions and insider buying
- Is STXS undervalued or overvalued?
- Stereotaxis Inc financial analysis — revenue, earnings, cash flow
- STXS Piotroski F-Score and Altman Z-Score
- STXS analyst price target and Smart Rating
Stereotaxis Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Stereotaxis Inc (STXS) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Stereotaxis Inc (STXS) Key Strengths (2)
Revenue surging 36.30% year-over-year
Good growth relative to its price
Supporting Valuation Data
Stereotaxis Inc (STXS) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 12.9x book value
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 5.4x annual revenue
Moderate institutional interest at 44.97%
Supporting Valuation Data
Stereotaxis Inc (STXS) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, PEG Ratio. Valuation metrics including PEG Ratio (1.31) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 36.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (5.38), Price/Book (12.91) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -143.60%, Operating Margin at -61.20%, Profit Margin at -66.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -143.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 36.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
STXS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
STXS's Price-to-Sales ratio of 5.38x trades at a deep discount to its historical average of 12.8x (36th percentile). The current valuation is 94% below its historical high of 84.28x set in Feb 2006, and 1045% above its historical low of 0.47x in Jun 2012. Over the past 12 months, the PS ratio has compressed from ~6.7x as trailing revenue scaled faster than the stock price.
Compare STXS with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Stereotaxis Inc (STXS) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Stereotaxis Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 32M with 36% growth year-over-year. The company is currently unprofitable, posting a -66.8% profit margin.
Key Findings
Revenue growing at 36% YoY, reaching 32M. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
The company is unprofitable with a -66.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Stereotaxis Inc maintain 36%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Stereotaxis Inc.
Bottom Line
Stereotaxis Inc is a high-conviction growth story with revenue accelerating at 36% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -66.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Stereotaxis Inc(STXS)
NYSE MKT
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (MRI) systems for use in the hospital's interventional operating room to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. The company is headquartered in St. Louis, Missouri.